0001104659-20-011789.txt : 20200310 0001104659-20-011789.hdr.sgml : 20200310 20200206134645 ACCESSION NUMBER: 0001104659-20-011789 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ArTara Therapeutics, Inc. CENTRAL INDEX KEY: 0001359931 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1 LITTLE WEST 12TH STREET CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 646-844-0337 MAIL ADDRESS: STREET 1: 1 LITTLE WEST 12TH STREET CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC DATE OF NAME CHANGE: 20060420 CORRESP 1 filename1.htm

 

ArTara Therapeutics, Inc.

1 Little West 12th Street

New York, NY 10014

(646) 844-0337

 

February 6, 2020

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:                    William Mastrianna

 

Re:                             ArTara Therapeutics, Inc.

Registration Statement on Form S-3

File No. 333-236173

 

Acceleration Request

 

Requested Date:

Monday, February 10, 2020

Requested Time: 

4:30 p.m. Eastern Time

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, ArTara Therapeutics, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on Monday, February 10, 2020, or as soon thereafter as is practicable.

 

Once the Registration Statement has been declared effective, please orally confirm that event with Ryan S. Sansom of Cooley LLP at (617) 937-2335 or Karen E. Deschaine of Cooley LLP at (858) 550-6088.

 

Sincerely,

 

ARTARA THERAPEUTICS, INC.

 

 

By:

/s/ Jesse Shefferman

 

 

Jesse Shefferman

 

 

President and Chief Executive Officer